
What happened
Pramaana Labs announced $27 million(約43億円) in seed funding led by Khosla Ventures, with participation from Accel, BoldCap, Nexus Venture Partners, Premji Invest, and Unbound. The startup will use formal verification tools—drawing on the LEAN programming language used to verify mathematical proofs—to add a deterministic verification layer on top of conventional LLMs, checking the AI's reasoning before it reaches users.
Why it matters
Enterprises are struggling to turn AI pilot programs into reliable business tools, especially in high-stakes fields where errors are costly. Pramaana's approach addresses this by formalizing the rules of domains like tax law and drug discovery into executable code, making the AI's reasoning deterministic and verifiable rather than opaque. This addresses a core pain point: current AI systems lack sufficient protection against hallucinations and errors in sensitive verticals.
What to watch
Pramaana is building domain-specific verification systems, starting with tax law (working with former IRS commissioner Danny Werfel) and cybersecurity and drug discovery (overseen by professors from IIT Delhi, IIT Madras, and UC Berkeley). The company's model requires codifying the rules of each industry before verification can work, making execution and domain expertise the critical path forward.
Ask the AI about this article →
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
AI giants are leaning into health care as a strategy to stall public backlash, according to Axios

Global funding to biotech startups has held between $36 billion and $40 billion for the past few years, and 20…

Researchers at Lille University Hospital in France rigged an LLM-based diagnostic support system to suggest a…

Social media conversations about Tempus AI intensified after Moderna and Merck reported Phase 3 success in per…

A Pew Research Center survey of 3,488 U.S

Nurses rallied in downtown Asheville on Thursday, Aug
